Sugi Predict

Sugi Predict / Compounds / SCHEMBL4132744

SCHEMBL4132744

SCHEMBL4132744

CC(C)(C)OC(=O)N[C@H]1C[C@H](F)CN(c2ccncc2N)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 2/20 0.41
▸ PDE10A Q9Y233 3/20 0.39
▸ EIF2AK4 Q9P2K8 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ JAK2 O60674 2/20 0.37
▸ JAK1 P23458 2/20 0.37
▸ KDM4D Q6B0I6 3/20 0.37
▸ CKS1B P61024 1/20 0.37
▸ SKP1 P63208 1/20 0.37
▸ SKP2 Q13309 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ BTK Q06187 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119084 1.00 MAP4K4 (0.41) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL15109521 0.93 MAP4K4 (0.44) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL13457022 0.93 MAP4K4 (0.44) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL15883435 0.90 MAP4K4 (0.40) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL18430014 0.90 MAP4K4 (0.40) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL2836000 0.90 MAP4K4 (0.40) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL30628530 0.90 MAP4K4 (0.40) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL2836002 0.90 MAP4K4 (0.40) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL2836325 0.89 EIF2AK4 (0.48) MAP4K4PDE10AEIF2AK4AURKAPDPK1
SCHEMBL11912156 0.89 EIF2AK4 (0.48) MAP4K4PDE10AEIF2AK4AURKAPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829193-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-09 — — US disclosed
US-8829193-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-09 — — US disclosed
EP-2262802-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-10-23 — — EP disclosed
US-20120202851-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-09 — — US disclosed
US-8168794-B2 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-01 — — US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 — — US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216839-A1 Pim kinase inhibitors and methods of their use PIM1, PIM2, PIM3 MAP4K4 50/4885PDE10A 1678/4885EIF2AK4 368/4885
US-20120202851-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MAP4K4 50/4885PDE10A 1678/4885EIF2AK4 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.